Cinobac en es it fr

Cinobac Brand names, Cinobac Analogs

Cinobac Brand Names Mixture

  • No information avaliable

Cinobac Chemical_Formula


Cinobac RX_link

Cinobac fda sheet

Cinobac FDA

Cinobac msds (material safety sheet)

Cinobac MSDS

Cinobac Synthesis Reference

No information avaliable

Cinobac Molecular Weight

262.218 g/mol

Cinobac Melting Point

261 oC

Cinobac H2O Solubility

No information avaliable

Cinobac State


Cinobac LogP


Cinobac Dosage Forms

Capsules (250mg and 500mg)

Cinobac Indication

For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K. pneumoniae), and Enterobacter species.

Cinobac Pharmacology

Cinoxacin is a synthetic antibacterial agent with in vitro activity against many gram-negative aerobic bacteria, particularly strains of the Enterobacteriaceae family. Cinoxacin inhibits bacterial deoxyribonucleic acid (DNA) synthesis, is bactericidal, and is active over the entire urinary pH range. Cross resistance with nalidixic acid has been demonstrated.

Cinobac Absorption

Rapidly absorbed after oral administration. The presence of food delays absorption but does does not affect total absorption.

Cinobac side effects and Toxicity

Oral, subcutaneous, and intravenous LD50 in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively. Oral, subcutaneous, and intravenous LD50 in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg, respectively.Symptoms following an overdose of cinoxacin may include anorexia, nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have been reported in some patients.

Cinobac Patient Information

Cinobac Organisms Affected

Enteric bacteria and other eubacteria